Haiwen & Partners is sought after by pharmaceutical, biotech, Chinese medicine, and cosmetics clients on a broad array of matters arising from the entire company and product life cycle. With healthcare and life sciences specialist Tina Wu at the helm, the firm is able to advise on licensing, clinical research regulatory issues, market access strategies, and data privacy. Rui Feng and Wenzhen Dai contribute to the group’s M&A expertise, and Frank Wang is experienced in intellectual property matters.
Legal 500 redaktioneller Kommentar
- Profil
Kernmandanten
- Beijing Synapsor Artificial Intelligence Technology Co., Ltd.
- Jianxin Financial Asset Investment Co., Ltd.
- Agricultural Bank Financial Assets Investment Co., Ltd.
- ICBC Financial Asset Investment Co., Ltd.
- Bank of Communications Financial Assets Investment Co., Ltd.
- Boc Financial Assets Investment Co., Ltd.
- Beijing Guo Rui Zhong Xin Equity Investment Fund (Limited Partnership)
- Huzhou CICC Qihe Equity Investment Partnership (Limited Partnership)
- Fuzhou CICC Jintou Emerging Digital Industry Investment Development Partnership (Limited Partnership)/Fuzhou CICC Rongtou Emerging Industry Investment Partnership (Limited Partnership)
Highlight-Mandate
- Advised on China Resources Pharmaceutical Commercial Group Co., Ltd.'s capital increase project.
- Advised on the investment of Huzhou CICC Qihe Equity Investment Partnership (Limited Partnership), a fund of CICC Capital, in Zhejiang TYK Medicines Co., Ltd.
Anwält*innen
Führende Partner*innen
Die stärksten Partner*innen ihres Praxisbereichs, die eine führende Rolle in signifikanten Mandaten einnehmen und weitreichende Anerkennung unter Wettbewerbern und Mandanten genießen.
Praxisleitung
Tina Wu
Weitere Kernanwält*innen
Rui Feng; Wenzhen Dai; Frank Wang